Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine February 2017, 58 (2) 8A;
  • Article
  • Info & Metrics
  • PDF
Loading

MR and PET in stroke: Heiss and Weber provide an overview of the complementarity and current state of the art of PET and MR imaging in differentiating irreversible tissue damage and critically hypoperfused but potentially salvageable tissue in stroke patients.

Page 187

PET lung image quantification: Chen and colleagues provide an educational overview of data evaluating 18F-FDG PET quantification approaches in lung diseases, focusing on methods to account for variations in lung components and interpretation of derived parameters.

Page 194

Commentary on SSTR antagonists: Hicks offers perspective on efforts to extend peptide receptor radionuclide therapy targeting the somatostatin receptor beyond neuroendocrine tumors and previews an article on this topic in this issue of JNM.

Page 196

MTV in lymphoma: Gallamini and Kostakoglu preview an article in this issue of JNM on the prognostic value of total metabolic tumor volume calculated by adaptive thresholding and emphasize the need for validated cutoff values in clinical practice.

Page 198

“Small data” innovation: Kesner and Weber argue for a paradigm shift in image data-saving practice toward more robust access and archiving, as a low-cost resource for innovation through informative details inherent within data or datasets.

Page 201

FETrp and AMT PET in PDX models: Michelhaugh and colleagues test in vivo uptake and kinetics of the novel tracer 18F-FETrp in patient-derived xenograft mouse models and compare them with 11C-AMT uptake to assess tryptophan metabolism.

Page 208

Imaging asparaginase biodistribution: van der Meer and colleagues explore the in vivo biodistribution of a radiolabeled version of the antileukemic drug asparaginase and provide evidence for tissue-specific clearance mechanisms that may affect the drug’s action.

Page 214

Oncolytic virus therapy: Wang and colleagues develop viral-based platforms with 2 specific gene reporters, human sodium iodide symporter and human somatostatin receptor 2, in the vaccinia-based oncolytic virus and test viral constructs for tracking and treating tumor development in vivo.

Page 221

68Ga-BBN-RGD PET: Zhang and colleagues report on first-in-human safety and efficacy PET studies with a 68Ga-labeled heterodimeric peptide bombesin-RGD that targets both integrin αvβ3 and gastrin-releasing peptide receptors.

Page 228

99mTc-PSMA-I&S for radiosurgery: Robu and colleagues describe development and initial animal and human biodistribution studies with this cost-effective kit for intraoperative prostate-specific membrane antigen targeting of small metastatic soft tissue lesions.

Page 235

Detecting ovarian sentinel nodes: Speth and colleagues report on a feasibility study comparing detection of sentinel nodes during surgery and on postresection SPECT/CT in patients with ovarian or endometrial cancer.

Page 243

Intraoperative fluorescence tumor imaging: Moore and colleagues assess the potential for repurposed intraoperative open-field imaging devices not specifically paired with an imaging agent to guide surgical management of solid tumors.

Page 246

Age and PET breast cancer staging: Lebon and colleagues compare rates of distant breast cancer metastasis on initial 18F-FDG PET/CT imaging in patients younger and older than 40 years.

Page 252

TERT mutation in thyroid cancer: Yang and colleagues examine the status of the telomerase reverse transcriptase promoter mutation in distant metastatic differentiated thyroid cancer and evaluate correlations among mutations, radioiodine uptake, and therapy response.

Page 258

Predicting esophageal pathologic response: Findlay and colleagues reevaluate current PET metabolic response assessment parameters for neoadjuvant chemotherapy in esophageal cancer and look at the potential utility of metabolic nodal stage and nodal response parameters.

Page 266

TMTV measurement in lymphoma: Cottereau and colleagues compare the prognostic value of baseline total metabolic tumor volumes measured on 18F-FDG PET/CT with adaptive thresholding methods or fixed SUVmax thresholds in patients with peripheral T cell lymphoma.

Page 276

CT density in PET-based LN staging: Giesel and colleagues explore correlations between SUVmax from PET and semiautomated CT density measurements in PET/CT differentiation of benign from malignant lymph nodes in various cancers.

Page 282

NAMPT inhibition and NETs: Elf and colleagues evaluate the potential of radiosensitizing effects from inhibition of nicotineamide phosphoribosyltransferase in 177Lu-DOTATATE treatment in a neuroendocrine tumor model.

Page 288

GRPR radioligand for theranostics: Dalm and colleagues report on the results of a preclinical study exploring the use of the gastrin-releasing peptide receptor antagonist NeoBOMB1 for theranostic applications by determining the biodistribution of 68Ga-NeoBOMB1 and 177Lu-NeoBOMB1.

Page 293

New tumor targets with sst2 antagonist: Reubi and colleagues quantitatively compare 125I-JR11 sst2 antagonist binding in vitro with that of the sst2 agonist 125I-Tyr3-octreotide in a variety of neuroendocrine and nonneuroendocrine tumors.

Page 300

68Ga-DOTATATE PET/CT interobserver agreement: Fendler and colleagues explore interpretation agreement between high- and low-experience observers in 68Ga-DOTATATE PET/CT imaging of 50 patients with neuroendocrine tumors.

Page 307

Response predictors for 177Lu-PSMA therapy: Ferdinandus and colleagues investigate the effects of different pretherapeutic parameters on therapeutic response with this prostate-specific membrane antigen in men with metastatic prostate cancer.

Page 312

11C-ER176 specific binding: Ikawa and colleagues determine in healthy volunteers whether the sensitivity of 11C-ER176, a translocator protein radioligand, is similar to the low sensitivity noted in vitro and assess the binding potential of 11C-ER176 in the human brain.

Page 320

11C-HED PET and denervation in PD: Wong and colleagues describe the results of a study of regional patterns of cardiac sympathetic denervation in idiopathic Parkinson disease using 11C-hydroxyephedrine PET to determine the denervation rate over 2 years.

Page 326

18F-AV-1451 kinetics in humans: Baker and colleagues evaluate the in vivo kinetics of the novel tau-specific PET radioligand 18F-AV-1451 in cognitively healthy controls and individuals with Alzheimer disease, using reference region analyses.

Page 332

Cellular dosimetry of 64Cu: Cai and colleagues model the cellular dosimetry of 64Cu under different geometries commonly used to study its cytotoxic effects.

Page 339

211At-induced systemic effects in mice: Langen and colleagues explore 211At tissue accumulation in targeted α-therapy, including effects on transcriptional regulation in various nonthyroid tissues induced, in part, by thyroid hormone–dependent signaling.

Page 346

  • © 2017 by the Society of Nuclear Medicine and Molecular Imaging.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 58 (2)
Journal of Nuclear Medicine
Vol. 58, Issue 2
February 1, 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Feb 2017, 58 (2) 8A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Feb 2017, 58 (2) 8A;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • Assessment of Tryptophan Uptake and Kinetics Using 1-(2-18F-Fluoroethyl)-l-Tryptophan and α-11C-Methyl-l-Tryptophan PET Imaging in Mice Implanted with Patient-Derived Brain Tumor Xenografts
  • Validation of MRI Determination of the Penumbra by PET Measurements in Ischemic Stroke
  • Comparison of Intraoperative γ-Probe Imaging and Postoperative SPECT/CT in Detection of Sentinel Nodes Related to the Ovary
  • Highly Increased 125I-JR11 Antagonist Binding In Vitro Reveals Novel Indications for sst2 Targeting in Human Cancers
  • Quantification of Lung PET Images: Challenges and Opportunities
  • 68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients
  • Enhancing Expression of Functional Human Sodium Iodide Symporter and Somatostatin Receptor in Recombinant Oncolytic Vaccinia Virus for In Vivo Imaging of Tumors
  • 2-Year Natural Decline of Cardiac Sympathetic Innervation in Idiopathic Parkinson Disease Studied with 11C-Hydroxyephedrine PET
  • Microarray Studies on 211At Administration in BALB/c Nude Mice Indicate Systemic Effects on Transcriptional Regulation in Nonthyroid Tissues
  • In Vivo Imaging of Antileukemic Drug Asparaginase Reveals a Rapid Macrophage-Mediated Clearance from the Bone Marrow
  • Characterizing the Utility and Limitations of Repurposing an Open-Field Optical Imaging Device for Fluorescence-Guided Surgery in Head and Neck Cancer Patients
  • Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer
  • Metabolic Tumor Volume: We Still Need a Platinum-Standard Metric
  • Rate of Distant Metastases on 18F-FDG PET/CT at Initial Staging of Breast Cancer: Comparison of Women Younger and Older Than 40 Years
  • Clinical Translation of a Dual Integrin αvβ3– and Gastrin-Releasing Peptide Receptor–Targeting PET Radiotracer, 68Ga-BBN-RGD
  • Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617
  • Correlation Between SUVmax and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging
  • 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology
  • Citius, Altius, Fortius: An Olympian Dream for Theranostics
  • Monte Carlo N-Particle (MCNP) Modeling of the Cellular Dosimetry of 64Cu: Comparison with MIRDcell S Values and Implications for Studies of Its Cytotoxic Effects
  • 11C-ER176, a Radioligand for 18-kDa Translocator Protein, Has Adequate Sensitivity to Robustly Image All Three Affinity Genotypes in Human Brain
  • TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer
  • Reference Tissue–Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging
  • NAMPT Inhibitor GMX1778 Enhances the Efficacy of 177Lu-DOTATATE Treatment of Neuroendocrine Tumors
  • Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma
  • Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemotherapy: The Implications of Metabolic Nodal Response for Personalized Therapy
  • Small Data: A Ubiquitous, Yet Untapped, Resource for Low-Cost Imaging Innovation
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire